These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32250758)

  • 1. Determination of
    Durán MT; Juget F; Nedjadi Y; Bochud F; Grundler PV; Gracheva N; Müller C; Talip Z; van der Meulen NP; Bailat C
    Appl Radiat Isot; 2020 May; 159():109085. PubMed ID: 32250758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ytterbium-175 half-life determination.
    Durán MT; Juget F; Nedjadi Y; Bochud F; Talip Z; van der Meulen NP; Köster U; Duchemin C; Stora T; Bailat C
    Appl Radiat Isot; 2021 Oct; 176():109893. PubMed ID: 34425350
    [No Abstract]   [Full Text] [Related]  

  • 3. Determination of the
    Collins SM; Gilligan C; Pierson B; Ramirez N; Goodwin M; Pearce AK; Archambault BC; Haney MM; Regan PH
    Appl Radiat Isot; 2022 Apr; 182():110140. PubMed ID: 35158282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity standardization, photon emission probabilities and half-life measurements of (177)Lu.
    Dryák P; Sochorová J; Šolc J; Auerbach P
    Appl Radiat Isot; 2016 Mar; 109():160-163. PubMed ID: 26653215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate.
    Haller S; Pellegrini G; Vermeulen C; van der Meulen NP; Köster U; Bernhardt P; Schibli R; Müller C
    EJNMMI Res; 2016 Dec; 6(1):13. PubMed ID: 26860295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fast digital 4πβ-4πγ coincidence counting with offline analysis at IRA.
    Teresa Durán M; Nedjadi Y; Juget F; Bochud F; Bailat C
    Appl Radiat Isot; 2018 Apr; 134():329-336. PubMed ID: 28988936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161.
    Juget F; Talip Z; Nedjadi Y; Durán MT; Grundler PV; Zeevaart JR; van der Meulen NP; Bailat C
    EJNMMI Phys; 2022 Mar; 9(1):19. PubMed ID: 35286498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
    Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
    Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.
    Lehenberger S; Barkhausen C; Cohrs S; Fischer E; Grünberg J; Hohn A; Köster U; Schibli R; Türler A; Zhernosekov K
    Nucl Med Biol; 2011 Aug; 38(6):917-24. PubMed ID: 21843788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice.
    Müller C; Fischer E; Behe M; Köster U; Dorrer H; Reber J; Haller S; Cohrs S; Blanc A; Grünberg J; Bunka M; Zhernosekov K; van der Meulen N; Johnston K; Türler A; Schibli R
    Nucl Med Biol; 2014 May; 41 Suppl():e58-65. PubMed ID: 24360901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the half-life of
    Dong J; Bai T; Hu Y; Zhang X; Fan J; Dai Y; Miao L; Yu X; Li Z
    Appl Radiat Isot; 2023 Mar; 193():110647. PubMed ID: 36603457
    [No Abstract]   [Full Text] [Related]  

  • 12. Half-life measurement of
    Durán MT; Juget F; Nedjadi Y; Bailat C; Grundler PV; Talip Z; van der Meulen NP; Casolaro P; Dellepiane G; Braccini S
    Appl Radiat Isot; 2022 Dec; 190():110507. PubMed ID: 36228535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic radionuclides: production and decay property considerations.
    Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
    J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the activity of
    Kossert K; Takács MP; Nähle O
    Appl Radiat Isot; 2020 Feb; 156():109020. PubMed ID: 32056694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.
    Uusijärvi H; Bernhardt P; Rösch F; Maecke HR; Forssell-Aronsson E
    J Nucl Med; 2006 May; 47(5):807-14. PubMed ID: 16644751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of
    Juget F; Nedjadi Y; Buchillier T; Bochud F; Bailat C
    Appl Radiat Isot; 2016 Dec; 118():215-220. PubMed ID: 27684452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy.
    Hindié E; Zanotti-Fregonara P; Quinto MA; Morgat C; Champion C
    J Nucl Med; 2016 May; 57(5):759-64. PubMed ID: 26912441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standardisation and precise determination of the half-life of (44)Sc.
    García-Toraño E; Peyrés V; Roteta M; Sánchez-Cabezudo AI; Romero E; Martínez Ortega A
    Appl Radiat Isot; 2016 Mar; 109():314-318. PubMed ID: 26701659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity determination and nuclear decay data of 177Lu.
    Kossert K; Nähle OJ; Ott O; Dersch R
    Appl Radiat Isot; 2012 Sep; 70(9):2215-21. PubMed ID: 22429554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of the 177Lu half-life.
    Pommé S; Paepen J; Altzitzoglou T; Van Ammel R; Yeltepe E
    Appl Radiat Isot; 2011 Sep; 69(9):1267-73. PubMed ID: 21550813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.